About Ascendis Pharma
Ascendis Pharma is an emerging Specialty Pharma company focused on endocrinology and central nervous system disorders. The company has a high-value pipeline, e.g. once-weekly growth hormone in Phase 2 and once-monthly paliperidone in pre-clinical development. In addition, Ascendis signed a large strategic partnership with sanofi-aventis in 2010 in the field of diabetic diseases including our once-weekly insulin.
Ascendis’s proprietary TransCon Prodrug Technology provides a sustainable pipeline. The technology enables transient covalent binding of peptides, proteins and small molecules via TransCon Linkers to polymers or our proprietary self-eliminating TransCon Hydrogel. TransCon Linkers are self-cleaving linkers that autohydrolyze at a precisely defined rate, ensuring predictable drug levels. Release kinetics can be controlled to support daily, weekly, monthly or quarterly administration for systemic and localized drug delivery.
© 2013 BioRN Cluster Management GmbH • All Rights Reserved • Contact & Legal Notice